Actively Recruiting
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
Led by AstraZeneca · Updated on 2026-04-22
24
Participants Needed
19
Research Sites
156 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This trial is a Phase 1b, open-label, multi-center, clinical study of AZD0120, a BCMA/CD19 dual targeting CAR+ T-cell therapy, to evaluate the safety and tolerability in adult participants with Multiple Sclerosis.
CONDITIONS
Official Title
An Open-label Study of AZD0120 in Adults With Multiple Sclerosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to 60 years at the time of consent
- Written informed consent according to guidelines
- Adequate physiological function and reserve at screening
- Diagnosis of relapsing MS (RMS) or active secondary progressive MS (SPMS) with EDSS 64 6.5 for RMS cohort
- Evidence of active disease or intolerance to high efficacy therapy for 65 6 months for RMS cohort
- Diagnosis of primary progressive MS (PPMS) or non-relapsing SPMS with EDSS between 3.0 and 6.5 for PMS cohort
- Inadequate response or intolerance to 65 1 high-efficacy disease-modifying therapy for 65 6 months for PMS cohort
You will not qualify if you...
- Prior exposure to CAR-T or CAR-NK cell therapy
- Splenectomy within 12 months before consent
- History of solid organ transplant or active transplant waiting list
- Prior autologous hematopoietic stem cell transplantation or total lymphoid irradiation
- Significant cardiac conditions posing undue risk
- Other central nervous system diseases affecting neurotoxicity evaluation, including epilepsy, stroke, dementia, Parkinson's, psychosis, or seizure disorders
- Significant psychiatric condition (active or history)
- Other immune-mediated diseases requiring ongoing systemic immunosuppression
- Clinically significant bleeding or active bleeding diathesis within 90 days before screening
- History or current malignancy treatment
- Inborn errors of immunity or primary immunodeficiency
- Seropositive for HIV or HTLV
- Active viral hepatitis (any type)
- Major surgery within 4 weeks before apheresis, lymphodepletion, or planned surgery during or within 4 weeks after treatment
- Pregnant, breastfeeding, or planning pregnancy during study or within 1 year after treatment
- Unable or unsafe to undergo cerebrospinal fluid exams or lumbar puncture
- Contraindications to lumbar puncture
- Unable or unwilling to undergo MRI scans as per protocol
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 19 locations
1
Research Site
Tucson, Arizona, United States, 85719
Withdrawn
2
Research Site
Aurora, Colorado, United States, 80045
Not Yet Recruiting
3
Research Site
Washington D.C., District of Columbia, United States, 20007
Not Yet Recruiting
4
Research Site
St Louis, Missouri, United States, 63110
Actively Recruiting
5
Research Site
New York, New York, United States, 10016
Not Yet Recruiting
6
Research Site
New York, New York, United States, 10032
Actively Recruiting
7
Research Site
Cleveland, Ohio, United States, 44195
Not Yet Recruiting
8
Research Site
Seattle, Washington, United States, 98104
Not Yet Recruiting
9
Research Site
Milwaukee, Wisconsin, United States, 53226
Not Yet Recruiting
10
Research Site
Liverpool, Australia, 2170
Not Yet Recruiting
11
Research Site
Melbourne, Australia, 3000
Actively Recruiting
12
Research Site
Melbourne, Australia, 3004
Not Yet Recruiting
13
Research Site
Waratah, Australia, 2298
Not Yet Recruiting
14
Research Site
Montreal, Quebec, Canada, H3A 1A1
Not Yet Recruiting
15
Research Site
Leipzig, Germany, 04103
Not Yet Recruiting
16
Research Site
Magdeburg, Germany, 39120
Not Yet Recruiting
17
Research Site
Würzburg, Germany, DE-97072
Not Yet Recruiting
18
Research Site
Cambridge, United Kingdom, CB2 2QQ
Not Yet Recruiting
19
Research Site
London, United Kingdom, SE5 9RS
Not Yet Recruiting
Research Team
A
AstraZeneca Clinical Study Information Center
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here